Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases

Purpose

The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data/outcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation.

Condition

  • Colorectal Cancer Metastatic

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 - Non-amenable to curative hepatic resection as defined by FLR <30% - Histologically confirmed adenocarcinoma of the colon or rectum - Candidate for LDLT for colorectal liver metastasis per the University of Rochester liver transplant program

Exclusion Criteria

  • Not a candidate of the LDLT liver transplant protocol for treatment of colorectal liver metastasis. - Unwilling to consent

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
All Participants Potential subjects for this registry must have Stage IV colorectal cancer with liver metastases and be candidates for liver transplantation based on multidisciplinary discussion by the Liver transplantation team. Patients must demonstrate favorable tumor biology and no evidence of extra hepatic disease.
  • Procedure: Liver transplantation
    living donor liver transplantation

Recruiting Locations

University of Rochester Medical Center
Rochester, New York 14642
Contact:
Roberto Hernandez-Alejandro, MD
roberto_hernandez@urmc.rochester.edu

More Details

NCT ID
NCT05248581
Status
Recruiting
Sponsor
University of Rochester

Study Contact

Roberto Hernandez-Alejandro, MD
585-275-5875
roberto_hernandez@urmc.rochester.edu

Detailed Description

The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data/outcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation. Our primary outcome of interest was the OS and recurrence-free survival (RFS) of patients who underwent LDLT at our center.